Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Procalcitonin Under the Course of Budesonide Inhalation Therapy in Recurrent Airway Obstruction (2016)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Barton, Ann Kristin (WE 17)
    Pelli, A.
    Rieger, Martin
    Gehlen, Heidrun (WE 17)
    Quelle
    Journal of Equine Veterinary Science; 45(Oktober) — S. 58–63
    ISSN: 0737-0806
    Sprache
    Englisch
    Verweise
    URL (Volltext): http://dx.doi.org/10.1016/j.jevs.2016.06.072
    Kontakt
    Klinik für Pferde, allgemeine Chirurgie und Radiologie

    Oertzenweg 19 b
    14163 Berlin
    +49 30 838 62299
    pferdeklinik@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Procalcitonin (PCT), a precursor protein of the hormone calcitonin, is a sensitive inflammatory marker useful in diagnosis of exacerbation of asthma and chronic obstructive pulmonary disease. In this study, PCT was evaluated as a potential biomarker for the success of budesonide inhalation therapy in equine recurrent airway obstruction (RAO). Twelve horses suffering from RAO were included in a prospective clinical study. Clinical examinations, exercise test, blood gas analysis, endoscopy, bronchoalveolar lavage fluid cytology, and thoracic radiography were performed before and after therapy and results included in a scoring system. Inhalative therapy using budesonide at a dosage of 1,500 μg twice daily was performed over 10 days. Equine-specific enzyme-linked immunosorbent assays were used to evaluate concentrations of PCT as well as interleukins-1ß and 6 in bronchoalveolar lavage fluid. A significant reduction in clinical score, in particular in dyspnea, amount, and viscosity of tracheal secretion, was found after 10 days of inhalation (P = .005). For PCT, no difference was found before and after therapy. The median PCT concentration increased insignificantly from 13.85 (6.8–42.09) ng/mL to 16.47 (2.04–151.01) ng/mL after therapy (P = .158). In conclusion, PCT does not seem to be a useful marker to monitor treatment success of glucocorticoid inhalation in RAO.